To Evaluate the Efficacy and Safety of Aspherical Soft Contact Lens in Myopia Control
A Prospective Randomized Control Study to Evaluate the Effect of Ticon Aspherical Daily Disposable Soft Contact Lens on Myopia Control
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Myopia (SE) between -1.00D to -8.00D
- Astigmatism less than or equal to 1.75D
- Myopia progression ≧0.75 D in the past 12 months
- Best Corrected Visual Acuity (BCVA): 0.9 Snellen or better
- Willingness to wear contact lens constantly
- Availability for follow-up for at least 1 year
- Parent's understanding and acceptance
- have an acceptable surrogate capable of giving legally authorized consent on behalf of the subject
Exclusion Criteria:
- Anisometropia greater than 2.00D
- Presence of ocular disease preventing wear of contact lens
- Severe ocular or systemic allergies
- Taking any medication that might have an impact on contact lens wear or that might influence the outcome of the clinical trial
- Ocular or systemic condition that might affect refractive development
- Atropine/Pirenzepine treatment for myopia control in the past 1 month
- Prior use of Ortho-K lenses
- Dry eye with Schimer Test (basal secretion test) < 5mm/5min or other physical condition that would contraindicate contact lens wear
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ticon Aspherical Daily Disposable Soft Contact Lens
The subject will be requested to wear lens 8 hours a day, 5 days a week at least.
The contact lens will be worn and replaced every day.
All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
|
|
|
Placebo Comparator: Ticon Daily Soft Contact Lens
The subject will be requested to wear lens 8 hours a day, 5 days a week at least.
The contact lens will be worn and replaced every day.
All subjects will be followed for 1 year post device allocation with a brief clinical assessment at 1 day, 1 week, 1, 3, 6, 9, 12 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spherical Equivalent Refraction (SER)
Time Frame: 12 months
|
The change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction over 12 months.
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Axial Eye Length (AXL)
Time Frame: 12 months
|
The change in axial eye length (AXL) measured over 12 months.
Axial length is measured after cycloplegia using optical biometry.
|
12 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Primary safety Endpoints
Time Frame: 12 months
|
All dispensed eyes over all follow-up visits.
Measured on a scale of 0-4 with 0=no findings and 4=severe findings.
Epithelial edema, epithelial microcysts, corneal staining, limbal & bulbar injection, conjunctival abnormalities, corneal neovascularization and infiltrates will be measured.
|
12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Tzu-Hsun Tsai, M.D., National Taiwan University Hospital
- Principal Investigator: Elizabeth P Shen, M.D., Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
- Principal Investigator: Hsiao-Sang Chu, M.D., National Taiwan University Hospital
- Principal Investigator: Han-Chih Cheng, M.D., Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1011128M
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.